Scipher Medicine

Scipher Medicine is a private, commercial-stage diagnostics company focused on transforming the treatment of autoimmune diseases through precision medicine. Its core asset is the PrismRA blood test, a commercially launched molecular signature test to predict response to anti-TNF therapy in rheumatoid arthritis, which has secured Medicare coverage. The company's foundation is its Spectra AI platform, which analyzes a vast registry of real-world clinico-genomic data to discover biomarkers, guide therapeutic development, and provide commercialization insights, supported by partnerships with pharmaceutical companies like Galapagos and Ionis.

The Spectra AI platform combines a map of human protein-protein interactions, a large real-world clinico-genomic data registry in autoimmune diseases, and proprietary AI algorithms to analyze disease biology and predict treatment response.

Scipher competes in the molecular diagnostics for autoimmune disease space, facing competition from other biomarker tests (e.g., multi-biomarker disease activity tests) and broader treatment guideline trends. Its unique differentiator is its foundation in network biology and large-scale real-world data. In drug discovery partnerships, it competes with other AI-driven biotech platforms.